You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 294 No. 21, December 7, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (36)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Medical Practice, Other
 •Oncology
 •Colon Cancer
 •Alert me on articles by topic

Adjuvant Chemotherapy for Stage III Colon Cancer

Implications of Race/Ethnicity, Age, and Differentiation

J. Milburn Jessup, MD; Andrew Stewart, MS; Frederick L. Greene, MD; Bruce D. Minsky, MD

JAMA. 2005;294:2703-2711.

Context  A 1990 National Institutes of Health Consensus Conference recommended that patients with stage III colon cancer receive adjuvant chemotherapy because survival was improved in clinical trials in patients who received a 5-fluorouracil–based regimen.

Objective  To determine whether adjuvant chemotherapy is used in the community as a standard of practice that improves outcome and whether it failed to benefit any specific sets of patients.

Design, Setting, and Participants  Prospective data from 85 934 patients with stage III colon cancer from 560 hospital cancer registries were entered into the National Cancer Data Base between 1990 and 2002 and included standard clinical, pathological, and first course of treatment variables.

Main Outcome Measures  Prevalence of adjuvant chemotherapy usage and 5-year survival in patients treated in US hospitals.

Results  Adjuvant chemotherapy use increased from 39% in 1991 to 64% in 2002 but was lower in black, female, and elderly patients. It improved 5-year survival from almost 8% in 1991 to more than 16% in 1997 compared with surgery alone. Adjuvant chemotherapy increases survival in elderly patients as much as it does in younger patients. However, the benefit of adjuvant chemotherapy in blacks and those with high-grade cancers is not as great.

Conclusions  Adjuvant chemotherapy use has increased from 1990 to 2002 for patients with stage III colon cancer with an associated increase in 5-year survival of 16%. The benefit of adjuvant chemotherapy seems to be lower in black patients and high-grade cancers. Women have the same benefit but are less often treated. Elderly patients have the same benefit as younger patients but are less frequently treated. New options for adjuvant therapy in 2004-2005 may further improve the outcome of patients with stage III colon cancer.


Author Affiliations: Department of Oncology, Georgetown University Medical Center, Washington, DC (Dr Jessup); Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Md (Dr Jessup); Cancer Department, American College of Surgeons, Chicago, Ill (Mr Stewart); Department of Surgery, Carolinas Medical Center, Charlotte, NC (Dr Greene); and Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (Dr Minsky).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Secular Trends in Mortality From Common Cancers in the United States by Educational Attainment, 1993-2001
Kinsey et al.
JNCI J Natl Cancer Inst 2008;100:1003-1012.
ABSTRACT | FULL TEXT  

Residual Treatment Disparities After Oncology Referral for Rectal Cancer
Morris et al.
JNCI J Natl Cancer Inst 2008;100:738-744.
ABSTRACT | FULL TEXT  

Adjuvant Chemotherapy for Stage III Colon Cancer: Do Physicians Agree About the Importance of Patient Age and Comorbidity?
Keating et al.
JCO 2008;26:2532-2537.
ABSTRACT | FULL TEXT  

Adjuvant Chemotherapy After Resection in Elderly Medicare and Medicaid Patients With Colon Cancer
Bradley et al.
Arch Intern Med 2008;168:521-529.
ABSTRACT | FULL TEXT  

The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States
Bilimoria et al.
Ann. Surg. Oncol. 2008;15:683-690.
FULL TEXT  

Association of Demographic and Treatment Variables in Long-Term Colon Cancer Survival
Lincourt et al.
SURG INNOV 2008;15:17-25.
ABSTRACT  

Adjuvant Therapy in the Elderly: Making the Right Decision
Muss et al.
JCO 2007;25:1870-1875.
ABSTRACT | FULL TEXT  

Adjuvant Treatment of Colorectal Cancer
Wolpin et al.
CA Cancer J Clin 2007;57:168-185.
ABSTRACT | FULL TEXT  

Increased prevalence of dihydropyrimidine dehydrogenase deficiency in african-americans compared with Caucasians.
Mattison et al.
Clin. Cancer Res. 2006;12:5491-5495.
ABSTRACT | FULL TEXT  

Colorectal Cancer Model of Health Disparities: Understanding Mortality Differences in Minority Populations
Polite et al.
JCO 2006;24:2179-2187.
ABSTRACT | FULL TEXT  

Progress in the Adjuvant Treatment of Colon Cancer: Has It Influenced Clinical Practice?
Van Cutsem and Costa
JAMA 2005;294:2758-2760.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.